Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $182.35M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.50M
Average 1.03M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Entera Bio Ltd. NASDAQ:ENTX | $541.57M | $3.11 | Not rated | -4.6 | +27.13% |
Agenus Inc. NASDAQ:AGEN | $304.51M | $6.73 | Not rated | 1.7 | +43.12% |
Turn Therapeutics Inc. NASDAQ:TTRX | $283.79M | $9.35 | Not rated | -45.0 | +218.82% |
Surrozen, Inc. NASDAQ:SRZN | $236.36M | $31.61 | Not rated | -0.7 | +123.22% |
Greenwich LifeSciences, Inc. NASDAQ:GLSI | $219.29M | $14.94 | Not rated | -15.6 | +142.52% |
Cognition Therapeutics, Inc. NASDAQ:CGTX | $64.65M | $0.68 | Not rated | -6.4 | -54.84% |
eXoZymes, Inc. NASDAQ:EXOZ | $35.55M | $3.83 | Not rated | -6.5 | -65.16% |
Continue the stock analysis
Jump to another research area for this company.